Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLLS NASDAQ:IRD OTCMKTS:JUSHF NASDAQ:RCKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$3.92$3.69$1.33▼$5.48$393.33M2.9421,539 shs37,525 shsIRDOpus Genetics$4.80$4.99$0.90▼$5.81$390.72M0.62996,277 shs917,726 shsJUSHFJushi$0.45$0.50$0.27▼$0.98$88.87M-0.67325,619 shs247,650 shsRCKTRocket Pharmaceuticals$3.25$3.94$2.19▼$6.89$354.87M0.522.04 million shs1.93 million shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis0.00%+1.82%-11.31%+5.09%+148.10%IRDOpus Genetics0.00%-3.81%-16.52%+31.87%+370.59%JUSHFJushi0.00%-12.35%-12.75%-12.16%+38.80%RCKTRocket Pharmaceuticals0.00%-10.47%-16.88%-0.61%-50.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$3.92$3.69$1.33▼$5.48$393.33M2.9421,539 shs37,525 shsIRDOpus Genetics$4.80$4.99$0.90▼$5.81$390.72M0.62996,277 shs917,726 shsJUSHFJushi$0.45$0.50$0.27▼$0.98$88.87M-0.67325,619 shs247,650 shsRCKTRocket Pharmaceuticals$3.25$3.94$2.19▼$6.89$354.87M0.522.04 million shs1.93 million shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis0.00%+1.82%-11.31%+5.09%+148.10%IRDOpus Genetics0.00%-3.81%-16.52%+31.87%+370.59%JUSHFJushi0.00%-12.35%-12.75%-12.16%+38.80%RCKTRocket Pharmaceuticals0.00%-10.47%-16.88%-0.61%-50.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis 2.83Moderate Buy$6.7572.19% UpsideIRDOpus Genetics 2.79Moderate Buy$10.20112.50% UpsideJUSHFJushi 3.00BuyN/AN/ARCKTRocket Pharmaceuticals 2.39Hold$11.54255.03% UpsideCurrent Analyst Ratings BreakdownLatest JUSHF, CLLS, RCKT, and IRD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026RCKTRocket Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026IRDOpus Genetics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$12.00 ➝ $11.005/12/2026IRDOpus Genetics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/11/2026RCKTRocket Pharmaceuticals Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/30/2026IRDOpus Genetics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/28/2026IRDOpus Genetics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform4/28/2026IRDOpus Genetics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$12.004/24/2026RCKTRocket Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026IRDOpus Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CLLSCellectis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/14/2026CLLSCellectis Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$8.00(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$79.59M4.94N/AN/A$0.76 per share5.16IRDOpus Genetics$14.20M27.52N/AN/A$0.22 per share21.82JUSHFJushi$262.91M0.34N/AN/A($0.59) per share-0.75RCKTRocket PharmaceuticalsN/AN/AN/AN/A$2.56 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$67.59M-$0.67N/AN/AN/A-89.51%-80.66%-20.51%7/30/2026 (Estimated)IRDOpus Genetics-$49.59M-$1.33N/AN/AN/A-892.36%-338.88%-191.21%5/21/2026 (Estimated)JUSHFJushi-$68.59M-$0.36N/AN/AN/A-26.90%N/A-16.59%8/4/2026 (Estimated)RCKTRocket Pharmaceuticals-$223.12M-$1.87N/AN/AN/AN/A-69.61%-58.63%8/6/2026 (Estimated)Latest JUSHF, CLLS, RCKT, and IRD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026IRDOpus Genetics-$0.16N/AN/AN/A$3.14 millionN/A5/12/2026Q1 2026IRDOpus Genetics-$0.16-$0.75-$0.59-$0.75$2.93 million$2.16 million5/12/2026Q1 2026JUSHFJushi-$0.06-$0.10-$0.04-$0.10$67.05 million$66.43 million5/11/2026Q1 2026CLLSCellectis-$0.2583-$0.18+$0.0783-$0.18$11.04 million$7.55 million5/7/2026Q1 2026RCKTRocket Pharmaceuticals-$0.41-$0.42-$0.01-$0.42$4.47 millionN/A3/31/2026Q4 2025JUSHFJushi-$0.06-$0.08-$0.02-$0.08$67.50 million$68.34 million3/19/2026Q4 2025CLLSCellectis-$0.10-$0.26-$0.16-$0.26$10.74 million$15.50 million2/26/2026Q4 2025RCKTRocket Pharmaceuticals-$0.42-$0.38+$0.04-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/AJUSHFJushiN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis1.131.521.52IRDOpus GeneticsN/A7.137.13JUSHFJushiN/A1.130.65RCKTRocket Pharmaceuticals0.086.126.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%IRDOpus Genetics14.97%JUSHFJushi21.68%RCKTRocket Pharmaceuticals98.39%Insider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%IRDOpus Genetics11.70%JUSHFJushi23.13%RCKTRocket Pharmaceuticals21.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis290100.34 million83.87 millionOptionableIRDOpus Genetics1481.40 million71.87 millionN/AJUSHFJushi1,288199.70 million153.51 millionNot OptionableRCKTRocket Pharmaceuticals240109.19 million85.94 millionOptionableJUSHF, CLLS, RCKT, and IRD HeadlinesRecent News About These CompaniesRocket Pharmaceuticals (NASDAQ:RCKT) Upgraded at Wall Street ZenMay 16 at 2:07 AM | americanbankingnews.comInsider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Sells 3,361 Shares of StockMay 15 at 9:03 AM | insidertrades.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of "Hold" from BrokeragesMay 13, 2026 | americanbankingnews.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by AnalystsMay 13, 2026 | marketbeat.comLifesci Capital Analysts Raise Earnings Estimates for RCKTMay 12, 2026 | marketbeat.comSarbani Chaudhuri Sells 17,650 Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) StockMay 12, 2026 | insidertrades.comRocket Pharmaceuticals' (RCKT) "Buy" Rating Reaffirmed at Chardan CapitalMay 12, 2026 | americanbankingnews.comRCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in FocusMay 11, 2026 | zacks.comRocket Pharmaceuticals (NASDAQ:RCKT) Receives "Buy" Rating from Chardan CapitalMay 11, 2026 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Announces Earnings ResultsMay 9, 2026 | marketbeat.comRocket Pharmaceuticals (RCKT) Projected to Post Quarterly Earnings on ThursdayMay 7, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI)April 29, 2026 | theglobeandmail.comRocket Pharmaceuticals Announces $180 Million Sale of Priority Review VoucherApril 28, 2026 | joplinglobe.comJLifesci Capital Has Pessimistic Outlook of RCKT Q1 EarningsApril 21, 2026 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by BrokeragesApril 18, 2026 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Merit Medical Systems (MMSI) and Vaxcyte (PCVX)April 16, 2026 | theglobeandmail.comRCKT Stock Down Despite FDA Nod to Gene Therapy in Rare DiseaseMarch 30, 2026 | zacks.comWhy Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADIMarch 29, 2026 | insidermonkey.comRocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 TranscriptMarch 27, 2026 | seekingalpha.comRocket Pharmaceuticals secures FDA approval for gene therapy KRESLADIMarch 27, 2026 | proactiveinvestors.caPRocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)March 27, 2026 | joplinglobe.comJNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJUSHF, CLLS, RCKT, and IRD Company DescriptionsCellectis NASDAQ:CLLS$3.92 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$3.92 0.00 (-0.13%) As of 06:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Opus Genetics NASDAQ:IRD$4.80 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$4.94 +0.15 (+3.02%) As of 06:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.Jushi OTCMKTS:JUSHF$0.45 0.00 (0.00%) As of 05/15/2026 03:59 PM EasternJushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.Rocket Pharmaceuticals NASDAQ:RCKT$3.25 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$3.26 +0.00 (+0.15%) As of 04:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
